Mountain View, CA-based MAP Pharmaceuticals announced that it is planning an IPO of 5 million shares of common stock at a price of between $14 and $16 per share. Money raised from the offering will be used to fund clinical work, among other things. MAP is developing inhaled drugs to treat pediatric asthma and migraines and is planning to launch two Phase III trial early next year.
- see the report from CNN Money
ALSO: Zars Pharma, a maker of topical pain relievers, has delayed its IPO until next week. Report